Amikacin

Amikacin

SCHEMBL1003907

N=C(N)NC(=O)c1nc(Cl)c(N)nc1N.NCC[C@H](O)C(=O)N[C@@H]1C[C@H](N)[C@@H](O[C@H]2O[C@H](CN)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](N)[C@H]1O

nearest known ligand 0.70

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Amikacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.70
ALOX15 P16050 3/20 0.69
RAD52 P43351 1/20 0.69
GJB2 P29033 4/20 0.46
GJA1 P17302 3/20 0.46
MEN1 O00255 1/20 0.46
CYP2C9 P11712 1/20 0.46
TSHR P16473 1/20 0.46
KMT2A Q03164 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.45
KDM4E B2RXH2 1/20 0.42
HPSE Q9Y251 1/20 0.39
CYP3A4 P08684 1/20 0.39
GAA P10253 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Amikacin SCHEMBL20770189 0.86 LMNA (0.52) LMNAALOX15RAD52GJB2GJA1
Amikacin SCHEMBL20516498 0.84 LMNA (1.00) LMNAALOX15RAD52GJB2GJA1
Amikacin SCHEMBL15263403 0.84 LMNA (1.00) LMNAALOX15RAD52GJB2GJA1
Amikacin SCHEMBL15515830 0.84 LMNA (1.00) LMNAALOX15RAD52GJB2GJA1
Amikacin SCHEMBL24437395 0.84 LMNA (1.00) LMNAALOX15RAD52GJB2GJA1
Amikacin SCHEMBL23308753 0.84 LMNA (1.00) LMNAALOX15RAD52GJB2GJA1
Amikacin SCHEMBL20522644 0.84 LMNA (1.00) LMNAALOX15RAD52GJB2GJA1
Amikacin SCHEMBL20516499 0.84 LMNA (1.00) LMNAALOX15RAD52GJB2GJA1
Amikacin SCHEMBL15171896 0.84 LMNA (1.00) LMNAALOX15RAD52GJB2GJA1
Amikacin SCHEMBL2637141 0.84 LMNA (1.00) LMNAALOX15RAD52GJB2GJA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1119345-A4 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GEN MILLS INC (US) 2004-06-16 EP claimed
US-20020044968-A1 High amount of plasticizer to facilitate plasticization of the matrix material at low shear and then reduced prior to adding the encapsulant to reduce post extrusion GENERAL MILLS, INC. 2002-04-18 US claimed
JP-2002511777-A 2002-04-16 JP claimed
EP-1119345-A1 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GENERAL MILLS, INC. (US) 2001-08-01 EP claimed
WO-2000021504-A1 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GENERAL MILLS, INC. (US) 2000-04-20 WO claimed
EP-0935523-A4 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES GEN MILLS INC (US) 1999-12-29 EP claimed
EP-0935523-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES GENERAL MILLS, INC. (US) 1999-08-18 EP claimed
WO-1998018610-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES LENGERICH BERNHARD H VAN (US) 1998-05-07 WO claimed
US-20230218874-A1 SWAB DELIVERY SYSTEM ANERGENT PHARMACEUTICALS, INC. (US) 2023-07-13 US disclosed
US-11623075-B2 Buccal swab delivery system ANERGENT PHARMACEUTICALS, INC. (US) 2023-04-11 US disclosed
US-11607392-B2 Encapsulation system for prolonged release of active agents TREND INNOVATIONS (CA) 2023-03-21 US disclosed
US-20200376241-A1 BUCCAL SWAB DELIVERY SYSTEM STATIM PHARMACEUTICALS, INC. (US) 2020-12-03 US disclosed
US-20200297648-A1 ENCAPSULATION SYSTEM FOR PROLONGED RELEASE OF ACTIVE AGENTS TREND INNOVATIONS (CA) 2020-09-24 US disclosed
US-10743604-B2 Articles of manufacture releasing an active ingredient NNTT TECH INC. (CA) 2020-08-18 US disclosed
EP-1065936-A1 ENCAPSULATION OF COMPONENTS INTO EDIBLE PRODUCTS GENERAL MILLS, INC. (US) 2001-01-10 EP disclosed
WO-2000021504-A1 ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES GENERAL MILLS, INC. (US) 2000-04-20 WO disclosed
EP-0935523-A4 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES GEN MILLS INC (US) 1999-12-29 EP disclosed
WO-1999048372-A1 ENCAPSULATION OF COMPONENTS INTO EDIBLE PRODUCTS GENERAL MILLS, INC. (US) 1999-09-30 WO disclosed
EP-0935523-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES GENERAL MILLS, INC. (US) 1999-08-18 EP disclosed
WO-1998018610-A1 EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES LENGERICH BERNHARD H VAN (US) 1998-05-07 WO disclosed